Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy

Kukreja, Janet Baack; Schroeck, Florian R.; Lotan, Yair; Gore, John L.; Ullman, Ralph; Lipman, Robert R.; Murray, Mary Beth Ballard; Chisolm, Stephanie; Smith, Angela

doi:10.1016/j.urolonc.2021.05.009

Cited by 9 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings were consistent with those of Schroeck et al, 24 who reported that frequent use of cystoscopy in the low-risk NMIBC setting was associated with a doubling in the number of TURBTs performed but was not associated with a decrease in the rates of progression or bladder cancer-specific mortality. Furthermore, Kukreja et al 25 recently found that most patients who received surveillance cystoscopy reported moderate to severe discomfort and anxiety, highlighting the substantial patient morbidity associated with current screening practices. Second, we found rates of surveillance testing significantly increased over the study period.…”

Section: Jama Network Open | Urologymentioning

confidence: 99%

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

et al. 2022

View full text Add to dashboard Cite

IMPORTANCE Low-risk non-muscle-invasive bladder cancer (NMIBC) is associated with extremely low rates of progression and cancer-specific mortality; however, patients with low-risk NMIBC may often receive non-guideline-recommended and potentially costly surveillance testing and treatment. OBJECTIVE To describe current surveillance and treatment practices, cancer outcomes, and costs of care for low-grade papillary stage Ta (low-grade Ta) NMIBC and identify factors associated with increased cost of care. DESIGN, SETTING, AND PARTICIPANTS This population-based cohort study identified 13 054 older adults (aged 66-90 years) diagnosed with low-grade Ta tumors in the Surveillance,

show abstract

Section: Jama Network Open | Urologymentioning

confidence: 99%

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[4,8] Patients may experience discomfort and restlessness owing to anxiety and stress. [9,10] The quality of care during the surgical procedure, effectiveness of drug and non-drug applications, pain prevention and relief applications, physiological and psychosocial well-being of patients, and meeting their expectations at an optimal level. [11] A review of studies evaluating nursing care for negative situations experienced by patients during cystoscopy found that listening to music during the procedure reduced patients' feelings of anxiety, pain, discomfort and dissatisfaction.…”

Section: Introductionmentioning

confidence: 99%

“…[8] Kukreja et al (2022) reported that, to reduce the discomfort experienced by patients, it is necessary to determine their experience and how they rate the care provided by healthcare professionals. [10] In a study of women undergoing cystoscopy, Tam et al (2023) found that when their emotional, physical, and informational needs were met, when they were actively involved in their health care, when they had a say in their care, their fear of the unknown decreased and patient satisfaction increased. [15] Biardeau et al (2017) found that the information given before cystoscopy had a negative effect on patient anxiety.…”

Section: Introductionmentioning

confidence: 99%

Quality of care perceived by patients during cystoscopy and affecting factors

Saray Kiliç,

Pazar,

İbrahimoğlu

et al. 2023

Medicine

View full text Add to dashboard Cite

It is necessary and important for quality of care to ensure the comfort of patients during the procedure, as well as before and after surgery. According to literature, it is necessary to know what patients experience and how they perceive the care they receive. This study aimed to investigate the quality of care perceived by patients during cystoscopy and the factors affecting it. This descriptive study was conducted in the surgical clinic of a teaching and research hospital, with 105 patients who underwent cystoscopy in 2022. Data collection forms consisting of a Sociodemographic and Disease Characteristics Questionnaire and the Good Perioperative Nursing Care Scale (for Patients) (GPNCS) were used for data collection, with face-to-face interviews on the first day after the procedure. This study was conducted in accordance with the principles of the Declaration of Helsinki. The study included patients with urinary tract stones, transurethral prostatectomy, and transurethral bladder resection. Of the participants, 72.4% were male, and 81.9% were married. The mean age of the patients was 50.09 ± 16.79 years. The mean total score was 143.56 ± 16.62. It was higher in single patients and those who had not previously undergone surgery. It was found that the mean of the environment sub-dimension was the highest at 18.57 ± 2.51 and the mean of the support sub-dimension was the lowest at 16.01 ± 3.44. The results of this study showed that patients undergoing cystoscopy have a good perception of the quality of their peri-operative nursing care.

show abstract

“… 3 Nonetheless, this is an invasive procedure, associated with severe discomfort and anxiety. 8 While UC is sensitive to high-grade lesions, it has limited diagnostic accuracy in low-grade bladder tumors. 9 Moreover, its interpretation is affected by various factors including collection procedure, low cellular yield, the presence of urinary infections, and interobserver variability.…”

Section: Introductionmentioning

confidence: 99%

AHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study

Komina¹,

Petruševska²,

Jovanović³

et al. 2022

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: This study aimed to measure the AHNAK2 urinary levels in bladder cancer patients. Material and methods: This prospective case–control study enrolled 67 participants between January and March 2019 and were categorized into bladder cancer group (n = 37), with histologically proven bladder cancer, and control group (n = 30), with histologically verified benign lesions or with no bladder cancer indication during follow-up. Urine samples of 15 mL were collected in the mid-morning before cystoscopy/surgery and an enzyme-linked immunosorbent assay was performed as per the manufacturer’s protocol. Bladder malignancies were classified according to the World Health Organization Tumor Classification. Group’s associations were evaluated with the Student t -test, Spearman’s rank correlation, and Mann–Whitney U test, while receiver operating curve was plotted for assessing the test’s performance. Results: Mean age of the bladder cancer group was 66.41 years (standard deviation = 10.04, range = 43-82 years) and the control group was 59.67 years (standard deviation = 10.44, range = 38-77 years). All bladder cancers were of the urothelial histotype, with the following pT distribution: pTa/papillary urothelial neoplasm of low malignant potential (n = 19; 28.4%), Primary tumor (pT) in situ (n = 4; 6%), pT1 (n = 7; 10.4%), and pT≥2 (n = 7; 10.48%). Mean AHNAK2 levels were higher in bladder cancer patients 49.08 pg/mL (standard deviation = 114.91) compared to controls 5.28 pg/mL (standard deviation = 6.65), P < .05). Significant differences were noted between non-invasive bladder cancer (n = 23; mean = 7.14 pg/mL; standard deviation = 7.26) and invasive bladder cancer (n = 14; mean = 117.99 pg/mL; standard deviation = 168.08) and between non-muscle invasive bladder cancer (mean = 23.19 pg/mL; standard deviation = 66.93) and muscle-invasive bladder cancer (mean = 160.05 pg/mL; standard deviation = 199.65) ( P < .001). The result of the assays was given as follows: sensitivity: 64.19%, specificity: 66.67%, positive predictive value: 22.07%, negative predictive value: 92.37%, area under curve: 0.695, and 95% CI: 0.57-0.82. Conclusion: AHNAK2 protein could be used as bladder cancer surveillance biomarker. The inclusion of AHNAK2 levels in stratification nomograms might reduce the number of unnecessary cystoscopies.

show abstract

Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy

Cited by 9 publications

References 10 publications

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

Quality of care perceived by patients during cystoscopy and affecting factors

AHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study

Contact Info

Product

Resources

About